Novartis AG (NVS) Stock

About Novartis AG

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG is led by CEO Vasant Narasimhan, employs 75,883 people, headquartered in Basel, CH, publicly traded since 1996.

Novartis AG (NVS) stock trades at $158.83 with a market capitalization of $301.89B. The stock is valued at a price-to-earnings (P/E) ratio of 20.60, price-to-book of 6.13, price-to-sales of 5.10. Over the past 52 weeks the stock has ranged between $112.34 and $170.46, and currently trades 6.8% below its 52-week high. It pays a dividend yielding 3.17%.

On profitability, Novartis AG generates a return on equity (ROE) of 30.47% — well above the market average, a sign of a high-quality business, return on capital employed of 36.68%, an operating margin of 31.15%, a net profit margin of 24.31%.

In its most recent fiscal year, Novartis AG reported annual revenue of $54.8B, net profit of $14.1B, revenue has compounded at 1.9% a year over the last five years, profit at 11.7% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 1.22, a current ratio of 1.12, total assets of $115.6B, $11.4B in cash and equivalents.

NVS has an average daily trading volume of 1,825,862 shares, a beta of 0.49 (less volatile than the overall market).

Official website: www.novartis.com